Longer-term use of electronic cigarettes when provided as a stop smoking aid: Systematic review with meta-analyses.

E-cigarette Electronic cigarette Longer term use Quitting smoking Smoking cessation Systematic review

Journal

Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116

Informations de publication

Date de publication:
12 2022
Historique:
received: 01 02 2022
revised: 22 06 2022
accepted: 30 07 2022
pubmed: 7 8 2022
medline: 7 12 2022
entrez: 6 8 2022
Statut: ppublish

Résumé

Moderate certainty evidence supports use of nicotine electronic cigarettes to quit smoking combustible cigarettes. However, there is less certainty regarding how long people continue to use e-cigarettes after smoking cessation attempts. We set out to synthesise data on the proportion of people still using e-cigarettes or other study products at 6 months or longer in studies of e-cigarettes for smoking cessation. We updated Cochrane searches (November 2021). For the first time, we meta-analysed prevalence of continued e-cigarette use among individuals allocated to e-cigarette conditions, and among those individuals who had successfully quit smoking. We updated meta-analyses comparing proportions continuing product use among individuals allocated to use nicotine e-cigarettes and other treatments. We included 19 studies (n = 7787). The pooled prevalence of continued e-cigarette use at 6 months or longer was 54% (95% CI: 46% to 61%, I

Identifiants

pubmed: 35933001
pii: S0091-7435(22)00231-6
doi: 10.1016/j.ypmed.2022.107182
pii:
doi:

Substances chimiques

Nicotine 6M3C89ZY6R

Types de publication

Meta-Analysis Systematic Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107182

Subventions

Organisme : Cancer Research UK
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ailsa R Butler (AR)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Electronic address: ailsa.butler@phc.ox.ac.uk.

Nicola Lindson (N)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Electronic address: nicola.lindson@phc.ox.ac.uk.

Thomas R Fanshawe (TR)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Electronic address: thomas.fanshawe@phc.ox.ac.uk.

Annika Theodoulou (A)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Electronic address: annika.theodoulou@phc.ox.ac.uk.

Rachna Begh (R)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Peter Hajek (P)

Wolfson Institute of Preventive Medicine, Barts, The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. Electronic address: p.hajek@qmul.ac.uk.

Hayden McRobbie (H)

National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia. Electronic address: h.mcrobbie@unsw.edu.au.

Chris Bullen (C)

National Institute for Health Innovation, University of Auckland, Auckland, New Zealand. Electronic address: c.bullen@auckland.ac.nz.

Caitlin Notley (C)

Norwich Medical School, University of East Anglia, Norwich, UK. Electronic address: c.notley@uea.ac.uk.

Nancy A Rigotti (NA)

Tobacco Research and Treatment Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: nrigotti@partners.org.

Jamie Hartmann-Boyce (J)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Electronic address: jamie.hartmann-boyce@phc.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH